#ES­MO22: Dizal touts win in niche NSCLC pop­u­la­tion cor­nered by Take­da, J&J

As­traZeneca spin­out Dizal said its can­cer drug cleared the pri­ma­ry goal in a Phase II tri­al of pa­tients with EGFR ex­on 20 in­ser­tion mu­ta­tions, for which Take­da and J&J have ap­proved meds, and oth­ers like Cul­li­nan On­col­o­gy and Blue­print Med­i­cines are at­tempt­ing to treat.

Send­ing out the da­ta in the ear­ly hours of this year’s Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy meet­ing in Paris, Dizal said 59.8% of pa­tients evalu­able as of the end of Ju­ly had a con­firmed ob­jec­tive re­sponse. The study, con­duct­ed in Chi­na, test­ed the break­through-des­ig­nat­ed sun­voz­er­tinib in plat­inum-pre­treat­ed non-small cell lung can­cer pa­tients who have EGFR ex­on 20 in­ser­tion mu­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER